Jazz Pharmaceuticals plc (JAZZ) Dividend History

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

Last update 08/13/2022


Dividend Yield Summary

  2017 2018 2019 2020 2021 2022
Dividends - - - - - -
Average Price 143.31 157.73 133.78 128.26 154.89 150.63
Yield - - - - - -
• The above Dividend, Average Price, and Yield values for 2022 are year-to-date.

Dividend History

No history of dividends
Date Amount Per Share Note